Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:DCTH NASDAQ:TMCI NASDAQ:ZJYL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$4.15-4.6%$3.40$1.60▼$16.55$308.05M1.18981,314 shs444,476 shsDCTHDelcath Systems$11.40-1.8%$14.28$7.17▼$18.23$404.33M0.87944,608 shs530,160 shsTMCITreace Medical Concepts$5.79-4.8%$5.93$4.54▼$10.79$382.37M0.69260,349 shs149,259 shsZJYLJin Medical International$0.66-5.3%$0.69$0.50▼$4.38$109.52M9.85232,907 shs231,793 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics+1.16%+6.62%+5.84%+79.75%-66.41%DCTHDelcath Systems+4.78%+3.20%-12.44%-3.73%+33.60%TMCITreace Medical Concepts+3.23%+3.93%+5.92%-8.71%-24.38%ZJYLJin Medical International+9.16%+9.52%+8.40%-18.65%-80.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.9849 of 5 stars4.61.00.00.00.60.80.0DCTHDelcath Systems2.6262 of 5 stars3.52.00.00.02.02.50.6TMCITreace Medical Concepts2.0998 of 5 stars3.22.00.00.00.63.30.6ZJYLJin Medical InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56202.54% UpsideDCTHDelcath Systems 3.00Buy$24.00110.53% UpsideTMCITreace Medical Concepts 2.33Hold$10.5281.64% UpsideZJYLJin Medical International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZJYL, DCTH, TMCI, and CATX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.60(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/ADCTHDelcath Systems$37.21M10.67N/AN/A$2.15 per share5.30TMCITreace Medical Concepts$209.36M1.74N/AN/A$1.81 per share3.20ZJYLJin Medical International$23.50M4.41$0.02 per share27.70$0.18 per share3.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)DCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/6/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.85N/AN/AN/A-25.14%-48.69%-24.59%8/5/2025 (Estimated)ZJYLJin Medical International$3.68MN/A0.00∞N/AN/AN/AN/AN/ALatest ZJYL, DCTH, TMCI, and CATX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ACATXPerspective Therapeutics-$0.30N/AN/AN/A$0.17 millionN/A8/6/2025Q2 2025DCTHDelcath Systems$0.02N/AN/AN/A$22.84 millionN/A8/5/2025Q2 2025TMCITreace Medical Concepts-$0.28N/AN/AN/A$47.08 millionN/A5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/AZJYLJin Medical InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60DCTHDelcath SystemsN/A15.9514.61TMCITreace Medical Concepts0.514.503.36ZJYLJin Medical InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%DCTHDelcath Systems61.12%TMCITreace Medical Concepts84.08%ZJYLJin Medical InternationalN/AInsider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%DCTHDelcath Systems17.40%TMCITreace Medical Concepts27.72%ZJYLJin Medical InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableDCTHDelcath Systems6034.83 million28.77 millionOptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableZJYLJin Medical International245156.55 millionN/ANot OptionableZJYL, DCTH, TMCI, and CATX HeadlinesRecent News About These CompaniesJin Medical International Ltd. Launches Production at New Intelligent Manufacturing Facility in Anhui, ChinaJuly 15, 2025 | quiverquant.comQJin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing FacilityJuly 15, 2025 | globenewswire.comJin Medical International (NASDAQ:ZJYL) Trading Up 2.7% - Should You Buy?July 10, 2025 | marketbeat.comJin Medical Faces Nasdaq Listing Compliance ChallengeMay 6, 2025 | tipranks.comJin Medical International Ltd. -- Nasdaq Minimum Bid Price Non-ComplianceMay 6, 2025 | gurufocus.comJin Medical International Ltd. – Nasdaq Minimum Bid Price Non-ComplianceMay 6, 2025 | globenewswire.comIs Jin Medical International Ltd.'s (NASDAQ:ZJYL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?April 28, 2025 | finance.yahoo.comJin Medical Boosts Production Capacity with New Chuzhou FacilityApril 25, 2025 | tipranks.comJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)April 13, 2025 | nasdaq.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Down 12.45%April 3, 2025 | aaii.comAWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 10.09%March 25, 2025 | aaii.comAWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Down 29.03%March 21, 2025 | aaii.comAWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 14.61%March 20, 2025 | aaii.comAWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 11.29%January 31, 2025 | aaii.comAJin Medical International Full Year 2024 Earnings: EPS: US$0.023 (vs US$0.02 in FY 2023)January 27, 2025 | finance.yahoo.comWuhan Jin Jiang International HotelNovember 12, 2024 | travelweekly.comTJin of BTS fronts rock band in 'I'll Be There' music videoOctober 25, 2024 | msn.comConstruction of JinMed's New Facility Begins in Chuzhou, ChinaOctober 10, 2024 | globenewswire.comSome Investors May Be Worried About Jin Medical International's (NASDAQ:ZJYL) Returns On CapitalOctober 9, 2024 | finance.yahoo.comZJYL Sees a Stock Surge of 5.04% Amid Positive Financial PerformanceOctober 2, 2024 | gurufocus.comCrude Oil Down Over 1%; US Manufacturing PMI Falls In SeptemberSeptember 24, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZJYL, DCTH, TMCI, and CATX Company DescriptionsPerspective Therapeutics NYSE:CATX$4.15 -0.20 (-4.60%) Closing price 04:00 PM EasternExtended Trading$4.21 +0.06 (+1.42%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Delcath Systems NASDAQ:DCTH$11.40 -0.21 (-1.81%) Closing price 04:00 PM EasternExtended Trading$11.42 +0.01 (+0.13%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Treace Medical Concepts NASDAQ:TMCI$5.79 -0.29 (-4.77%) Closing price 04:00 PM EasternExtended Trading$5.79 0.00 (0.00%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Jin Medical International NASDAQ:ZJYL$0.66 -0.04 (-5.35%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.02 (+2.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
